daratumumab

01/01/2020 - "Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies."
05/01/2020 - "Conclusion: Daratumumab is highly effective in relapsed and refractory multiple myeloma. "
01/01/2020 - "During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. "
12/01/2022 - "Subcutaneous daratumumab is non-inferior to intravenous daratumumab for the treatment of multiple myeloma and significantly reduced incidence of systemic reactions. "
01/01/2022 - "Background: The introduction of daratumumab into the treatment of multiple myeloma has improved outcomes in patients; however, community oncologists often dose more frequently than the US FDA-approved label. "

11/01/2020 - "This study demonstrates that daratumumab is highly effective in the treatment of previously treated AL amyloidosis, and a significant proportion of patients can achieve deep hematologic responses, as well as improvements in organ function."
01/01/2021 - "Daratumumab proved to be highly effective in newly diagnosed AL amyloidosis with excellent hematologic and organ response rates, a remarkable safety profile, and good tolerability even in patients with advanced stage of disease."
01/01/2020 - "Daratumumab is highly effective in heavily pretreated patients with relapsed/refractory AL amyloidosis and high bone marrow plasma cell burden. "
01/01/2019 - "Daratumumab proves safe and highly effective in AL amyloidosis."
09/01/2020 - "Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis."

01/01/2022 - "However, clinical trials have surprisingly shown that daratumumab monotherapy has not been very effective in these other blood malignancies. "
01/01/2022 - "Thus, it is important to consider factors modulating the determinants of response to CD38 targeting across different blood malignancies, encompassing both the transcriptional and post-transcriptional levels so that we can diversify the strategy to enhance daratumumab therapeutic efficacy, which can ultimately improve patient outcomes."
01/01/2022 - "In the late therapeutic treatment of established tumors Daratumumab followed by SOT101 administration or a concomitant administration of both drugs showed a significant anti-tumor efficacy over the respective monotherapies. "
01/01/2017 - "Decreasing daratumumab clearance with increasing dose suggests saturation of target-mediated clearance at higher dose levels, whereas decreasing clearance over time with repeated dosing may be due to tumor burden reductions as CD38-positive cells are eliminated. "
01/01/2019 - "MicroSPECT/CT imaging demonstrated fast clearance of the radiolabeled daratumumab from the circulation and tissues, but prolonged retention in the tumor up to 10 days. "

01/01/2018 - "He was treated with daratumumab monotherapy in the SIRIUS clinical trial resulting in a stringent complete response and clearance of minimal residual disease. "
02/01/2021 - "The addition of daratumumab to triplet regimens yielded modestly improved responses with significantly increased rates of minimal residual disease negativity but survival results were limited by short follow-up. "
09/22/2023 - "Our results suggest that daratumumab-based regimens are effective in the treatment of RRMM, improving progression-free survival, minimal residual disease, and overall response rate. "
11/01/2022 - "The addition of daratumumab to RVd and VTd has been investigated in the GRIFFIN and CASSIOPEIA trials, respectively, resulting in improvement in the rate of minimal residual disease (MRD) negativity. "
09/22/2023 - "the rate of minimal residual disease was also significantly higher in the daratumumab-based regimens (RR = 6.10, 95% CI 4.09-9.11, P < .00001). "

07/13/2023 - "Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival."
03/01/2023 - "The aim of this study is to assess the budget impact of daratumumab for light-chain amyloidosis in Cyprus. "
01/01/2020 - "A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis."
11/01/2023 - "A total of 189 patients diagnosed with MM or light chain amyloidosis were included in this retrospective study, and all subjects were daratumumab-naïve. "
03/01/2023 - "A budget impact model assessed the cost prior and after the introduction of daratumumab for light-chain amyloidosis. "